Sterne Agee CRT Upgrades Humana (HUM) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
- Dara Khosrowshahi steps down from Grab Holdings board
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
AbbVie (ABBV) Will Present Data from 30+ Abstracts at EULAR 2015
June 4, 2015 7:06 AM EDT(This article was updated with correct company name and ticker.)
AbbVie (NYSE: ABBV) announced that data from more than 30 abstracts on HUMIRA (adalimumab), investigational medicines and rheumatologic diseases will be presented at the 16th European League Against Rheumatism Annual Congress (EULAR), June 10 - 13 in Rome. Abstracts to be presented include data from a Phase 3 pivotal trial evaluating the efficacy and safety of HUMIRA as an investigational treatment for patients with non-infectious intermediate, posterior, or panuveitis, insights into the real-world impact of rheumatologic diseases, and new research on AbbVie's investigational medicines for rheumatoid... More
